Biotechnology
Compare Stocks
2 / 10Stock Comparison
ANVS vs ATHA
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
ANVS vs ATHA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $62M | $17M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-29M | $-129M |
| Total Debt | $0.00 | $803K |
| Cash & Equiv. | $19.53B | $69M |
ANVS vs ATHA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| Annovis Bio, Inc. (ANVS) | 100 | 47.2 | -52.8% |
| Athira Pharma, Inc. (ATHA) | 100 | 2.6 | -97.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANVS vs ATHA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ANVS has the current edge in this matchup, primarily because of its strength in growth exposure and long-term compounding.
- EPS growth 99.9%
- -76.3% 10Y total return vs ATHA's -97.5%
- 100.4% revenue growth vs ATHA's -64.6%
ATHA is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.47
- Lower volatility, beta 1.47, Low D/E 2.9%, current ratio 1.88x
- Beta 1.47, current ratio 1.88x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 100.4% revenue growth vs ATHA's -64.6% | |
| Stability / Safety | Beta 1.47 vs ANVS's 2.16 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +81.6% vs ANVS's +43.7% | |
| Efficiency (ROA) | -0.5% ROA vs ATHA's -225.7% |
ANVS vs ATHA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ATHA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ANVS and ATHA operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$30M | -$110M |
| Net IncomeAfter-tax profit | -$29M | -$129M |
| Free Cash FlowCash after capex | -$853M | -$52M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +16.7% | +24.8% |
Valuation Metrics
ANVS leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $62M | $17M |
| Enterprise ValueMkt cap + debt − cash | -$19.5B | -$30M |
| Trailing P/EPrice ÷ TTM EPS | -1.62x | -0.17x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.00x | 0.37x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ANVS leads this category, winning 5 of 5 comparable metrics.
Profitability & Efficiency
ANVS delivers a -0.7% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-4 for ATHA.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -0.7% | -3.8% |
| ROA (TTM)Return on assets | -0.5% | -2.3% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -0.3% | -2.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | -$19.5B | -$68M |
| Cash & Equiv.Liquid assets | $19.5B | $69M |
| Total DebtShort + long-term debt | $0 | $803,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (Dividends Reinvested)
ANVS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ANVS five years ago would be worth $967 today (with dividends reinvested), compared to $235 for ATHA. Over the past 12 months, ATHA leads with a +81.6% total return vs ANVS's +43.7%. The 3-year compound annual growth rate (CAGR) favors ANVS at -46.5% vs ATHA's -46.7% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -37.8% | -37.6% |
| 1-Year ReturnPast 12 months | +43.7% | +81.6% |
| 3-Year ReturnCumulative with dividends | -84.7% | -84.8% |
| 5-Year ReturnCumulative with dividends | -90.3% | -97.7% |
| 10-Year ReturnCumulative with dividends | -76.3% | -97.5% |
| CAGR (3Y)Annualised 3-year return | -46.5% | -46.7% |
Risk & Volatility
ATHA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ATHA is the less volatile stock with a 1.47 beta — it tends to amplify market swings less than ANVS's 2.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATHA currently trades 51.9% from its 52-week high vs ANVS's 41.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.16x | 1.47x |
| 52-Week HighHighest price in past year | $5.50 | $8.36 |
| 52-Week LowLowest price in past year | $1.44 | $2.30 |
| % of 52W HighCurrent price vs 52-week peak | +41.3% | +51.9% |
| RSI (14)Momentum oscillator 0–100 | 63.5 | 38.4 |
| Avg Volume (50D)Average daily shares traded | 889K | 46K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
ANVS leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). ATHA leads in 2 (Income & Cash Flow, Risk & Volatility).
ANVS vs ATHA: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — ANVS or ATHA?
Over the past 5 years, Annovis Bio, Inc.
(ANVS) delivered a total return of -90. 3%, compared to -97. 7% for Athira Pharma, Inc. (ATHA). Over 10 years, the gap is even starker: ANVS returned -76. 3% versus ATHA's -97. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — ANVS or ATHA?
By beta (market sensitivity over 5 years), Athira Pharma, Inc.
(ATHA) is the lower-risk stock at 1. 47β versus Annovis Bio, Inc. 's 2. 16β — meaning ANVS is approximately 47% more volatile than ATHA relative to the S&P 500.
03Which is growing faster — ANVS or ATHA?
On earnings-per-share growth, the picture is similar: Annovis Bio, Inc.
grew EPS 99. 9% year-over-year, compared to 2. 0% for Athira Pharma, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — ANVS or ATHA?
Annovis Bio, Inc.
(ANVS) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Athira Pharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANVS leads at 0. 0% versus 0. 0% for ATHA. At the gross margin level — before operating expenses — ANVS leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ANVS or ATHA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is ANVS or ATHA better for a retirement portfolio?
For long-horizon retirement investors, Athira Pharma, Inc.
(ATHA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Annovis Bio, Inc. (ANVS) carries a higher beta of 2. 16 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATHA: -97. 5%, ANVS: -76. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ANVS and ATHA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.